Andrew Alliance, Geneva, and Arcis Biotechnology, Daresbury, UK, have announced a comarketing relationship for deploying protocols that automate sample preparation for nucleic acid analysis on Andrew Alliance platforms. Under the terms of the agreement, Andrew Alliance and Arcis will promote the use of Arcis reagents for DNA and RNA preparation in conjunction with Andrew Alliance platforms, such as the Andrew+ pipetting robot and OneLab software.
Peter Whitehurst, Arcis Biotechnology.
“We are excited to announce this relationship with Andrew Alliance,” says Arcis CEO Peter Whitehurst. “The Andrew+ robot combined with our Arcis reagents represent a hands-free solution for stabilizing and preparing samples for RNA or DNA analysis, especially in infectious disease detection workflows, where speed is a key requirement.”
The design of the Andrew+ pipetting robot benefits from 6 years of user feedback. Andrew+ offers fully automated pipetting, as well as more complex manipulations, using a wide range of Domino accessories and Andrew Alliance electronic pipettes. It executes OneLab protocols, enabling rapid transition from laborious manual procedures to error-free, robotic workflows.
“Our agreement with Arcis will support our customers using a single platform to not only complete sample preparation, but also prepare for downstream analysis,” says Piero Zucchelli, CEO of Andrew Alliance. “This simple protocol reduces hands-on time as well as total time spent on getting samples ready for analysis, while not requiring anything more than Andrew+.”
Arcis reagents provide an ultrafast system for the preparation of DNA and RNA samples, with the added benefit of preserving and protecting nucleic acids without temperature control or additional processing. The fast and convenient protocol uses a simple two-step process that enables users to go from sample to amplifiable DNA or RNA in less than 3 minutes. The kits are compatible with blood plasma, cell cultures, food, soil, sputum, urine, whole blood, and many other sample types. The nucleic acids are suitable for direct use in downstream processes, including polymerase chain reaction, isothermal amplification, and sequencing.
For further information, visit Arcis Biotechnology.
